Navigation Links
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Date:11/7/2007

t products and bring to market products in development; depend upon third parties to manufacture or fill our products; achieve approval and market acceptance of our products; expand our sales and marketing capabilities or enter into and maintain arrangements with third parties to market and sell our products; effectively and/or profitability use, or utilize the full capacity of, our vaccine manufacturing facility; manufacture NicVAX(R) or other products in our own vaccine manufacturing facility; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report for the quarters ended June 30, 2007 and March 31, 2007 on Form 10-Q with the Securities and Exchange Commission.


'/>"/>
SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MUMBAI, India , September 17, 2014 ... TRPA1 antagonist, GRC 17536, has shown positive data in ... with painful diabetic neuropathy , ... Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 ... blind, placebo controlled, multi-centre, proof of concept study conducted ...
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... 2014 According to a new ... Battery, Memory Device, Display, & Microprocessor/MCU), by Application (Imaging, ... by Geography - Global Forecast to 2020", published by ... expected to reach $56.50 Billion by 2020, growing at ... Browse 235 market data Tables and 71 Figures ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
(Date:9/17/2014)... 2014 North Central Surgical Center is ... awards for their top-notch services. The hospital was the ... and GYN surgery. , Hospital-wide, North Central was the ... have received this award for two years in a ... percent in the nation for Patient Safety in 2014 ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- A blood ... could provide doctors with a better assessment of the ... If used routinely, this blood test could ... working and actually begins promoting tumor growth, the researchers ... given to patients with advanced prostate cancer and often ...
(Date:9/17/2014)... York, New York (PRWEB) September 17, 2014 ... filings involving the Conserve line of metal-on-metal hip ... now underway in U.S. District Court, Northern District ... an updated Case List issued by the U.S. ... 2014, at least 397 product liability claims have ...
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans at ... Americans, and prone to develop the disease at lower ... in the transition from traditional high-fiber, low-fat Asian diets ... for those of Asian heritage, says George King, M.D., ... Diabetes Center and the senior author of the study. ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace ... focusing on molecular diagnostics for conditions such as infectious ... The IVD market value is projected to be worth ... The major drivers of the market’s growth include the ... evidenced by the explosion for raid and minimally-invasive diagnostic ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... , , , , , , ... (NYSE: MR ), a leading developer, manufacturer and,marketer ... annual general meeting of shareholders held in Hong Kong on,December ... Mindray Medical International,s shareholders approved the,re-election of directors Mr. Xu ...
... nutrition but not physical activity needs, study finds , ... providers meet nutrition standards but don,t give children enough ... in front of the TV, a new study contends. ... 300 home-based child-care providers who looked after children ages ...
... ... a family secret and its shattering consequences, won two prestigious honors: a place on ... one of only 20 to receive the coveted award. , ... Washington, DC (PRWEB) December 18, 2009 -- ...
... , , BIRMINGHAM, Ala., Dec. 18 HealthSouth Corporation (NYSE: ... J.P. Morgan Healthcare Conference in San Francisco on Jan. 11-14, 2010. ... speaking on Monday, Jan. 11, 2010 at 11:30 a.m. PST. The ... http://investor.healthsouth.com by clicking on an available link. , ...
... , WASHINGTON, Dec. 18 Since 1984, Demographic and ... U.S. Agency for International Development (USAID), has collected and ... decision makers to plan, monitor, and evaluate population, health, ... conduct some 260 surveys in over 90 developing countries. ...
... Atyical response to self-relevant thoughts may help explain interpersonal ... brains of autistic people are less active than expected ... helps explain autism-related social difficulties, say British researchers. , ... 66 males, half of whom had autism, while they ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:Kids in Home-Based Day Care Lack Exercise 2Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 2Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 3Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 4Health News:HealthSouth to Present at J.P. Morgan Healthcare Conference 2Health News:USAID Celebrates 25 Years of Demographic and Health Surveys 2Health News:Brain Imaging Sheds Light on Social Woes Related to Autism 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: